Fasting in Medical Technology
Navigation Links
Fasting in Medical Technology
... reaching pre-defined A1C goals * Superior fasting blood glucose levels * Better early ... product, including its positive effects on fasting glucose levels.
Technosphere Insulin promises to ... group).
Over the 52-week period of the study, fasting blood glucose (FBG)
levels decreased ...
... weight. The percentage of patients with a fasting glucose increase from normal to high at any time ... should undergo baseline and periodic fasting blood glucose testing. Patients who develop ... of hyperglycemia during treatment should undergo fasting blood glucose testing. Undesirable alterations ...
... fixed ranges of 100 - 300 days, the BMI and the fasting blood glucose levels were compared and ... in the control group. Among patients with a fasting blood glucose of greater than 100 mg/dl, 57% of ... BMI reduction and improvements in blood fasting glucose. Key contributors to the study included ...
... LDL cholesterol and triglycerides Glycemic Parameters: fasting glucose, fasting insulin and insulin resistance Inflammatory Markers of ...
... treatment with APS who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. Hyperprolactinemia: As with other drugs that ...
... those with risk factors for diabetes should undergo baseline and periodic fasting blood glucose testing. Patients who develop symptoms of hyperglycemia during treatment should undergo fasting blood glucose testing. Undesirable alterations in lipids have been ...
... that the oral formulation of GLP-1 stimulated an early increase in fasting insulin and a decrease in fasting glucose as compared to placebo. "An intravenous or subcutaneous ...
... sustained a similar improvement in glucose control [A1C: -2.0%+/-0.08; fasting plasma glucose (FPG) -47+/-3 mg/dL] compared to those receiving treatment ... on exenatide once weekly showed sustained improvements in A1C and fasting plasma glucose levels at week 52 [A1C: -2.0%+/-0.1; FPG -47+/-3 mg/dL (LS ...
... with exenatide also resulted in a statistically significant lowering of fasting glucose concentrations for EXE 5 mcg (-17.5+/-4 mg/dL) and EXE 10 mcg ... (+4.5+/-14 mg/dL) in patients treated with placebo. In addition, fasting serum lipid profiles, including total cholesterol and high- and ...
... to 2 years. Lantus(R) was injected once-daily and titrated to capillary fasting blood glucose 70-100 mg/dL. In the lifestyle management arm, dietary and ... A1C <7% at endpoint. Secondary endpoints included changes in A1C and fasting plasma glucose (FPG), and hypoglycemia incidence. 211 (52.6% male) ...
... antipsychotics who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and periodically during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. A potentially fatal symptom complex, sometimes ...
... antipsychotics who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and periodically during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. A potentially fatal symptom complex, sometimes ...
... with risk factors for diabetes should undergo baseline and periodic fasting blood glucose testing. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. There have been few reports of hyperglycemia ...
... starting on atypical antipsychotics should undergo baseline and periodic fasting blood glucose testing. Patients who develop symptoms of hyperglycemia during treatment should undergo fasting blood glucose testing. Undesirable alterations in lipids have been ...
... lowers plasma insulin levels in diet-induced obese (DIO) mice and improves fasting blood glucose and glucose tolerance in hyperglycemic animal models, and ... sensitivity, lowering of plasma insulin levels and durable improvements in fasting blood glucose and glucose tolerance. "This encouraging preclinical work ...
... antipsychotics who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and periodically during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. A potentially fatal symptom complex, sometimes ...
... (adenosine monophosphate activated protein kinase) for the treatment of diabetes and metabolic diseases. Activation of AMPK has been shown to lower fasting blood glucose levels and improve glucose disposal following a glucose challenge, two key goals in the management of type 2 diabetes. Under the ...
... compounds or its active metabolite have demonstrated reductions in blood pressure, triglycerides, cholesterol levels, C-reactive protein, and fasting blood glucose levels. Enzyme levels indicative of liver damage, such as ALT and AST, are decreased, pointing to an outstanding safety profile. ...
... of treatment with exenatide once weekly for all patients during an open-ended assessment period. Significant reductions in A1C of 1.7 percent and fasting plasma glucose (FPG) of 40 mg/dL were maintained after two years of treatment. Sixty-five percent of patients achieved an A1C of 7 percent or less. ...
... effectively lower blood sugar after two years of treatment is consistent with its other long-term clinical benefits such as continued reductions in fasting blood sugar and weight," said Dr. Alan Garber, Baylor College of Medicine , Houston, a LEAD(TM) 3 principal study investigator. "Even with ...
... in A1C. Secondary objectives were proportion of subjects reaching specific A1C levels and treatment differences in postprandial plasma glucose (PPG), fasting plasma glucose (FPG), and weight. A1C was reduced by -0.66% and -0.72% in the TI+G and BPA 70/30 groups, respectively, and the proportion of ...
... in men and <50 mg/dL in women -- Blood pressure greater than or equal to 130/85 mmHg (or on antihypertensive treatment) -- Elevated fasting plasma glucose (greater than or equal to 100 mg/dL). What is meant by number needed to treat? The NNT value provides a clinical ...
... significantly better mean daytime blood glucose (BG)(p=0.0033), postprandial blood glucose (PPBG)(p<0.0001) and a more pronounced decrease of fasting blood glucose (FBG) (p=0.0684) versus pre-mixed insulins. Patients on intensified LANTUS(R) and APIDRA(R) therapy also tended to experience fewer ...
... 0.17 Mean change in systolic blood pressure from baseline, mmHg -6.7* -5.6* -1.1 *p FPG, fasting plasma glucose; OAD, oral antidiabetic drug; PPG, post-prandial glucose Safety and tolerability of liraglutide There were no major hypoglycemic ...
... weight. The percentage of patients with a fasting glucose increase from normal to high at any time ... should undergo baseline and periodic fasting blood glucose testing. Patients who develop ... of hyperglycemia during treatment should undergo fasting blood glucose testing. Undesirable alterations ...
... fixed ranges of 100 - 300 days, the BMI and the fasting blood glucose levels were compared and ... in the control group. Among patients with a fasting blood glucose of greater than 100 mg/dl, 57% of ... BMI reduction and improvements in blood fasting glucose. Key contributors to the study included ...
FDA Advisory Committee Votes in Favor of Zyprexa for Two Adolescent Indications
... glucose control. Patients starting treatment with Zyprexa should undergo fasting blood glucose testing at the beginning of treatment and periodically ... who develop symptoms of hyperglycemia during treatment should undergo fasting blood glucose testing. Undesirable alterations in lipids have been ...Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes
... to placebo in reducing key measures of glycemic control, including fasting serum glucose and hemoglobin A1C (HbA1C). In this study, LY2189265 showed ... from baseline in HbA1C; additional endpoints evaluated included changes in fasting serum glucose, solid mixed meal glucose excursion and body weight. ...Boehringer Ingelheim Unveils Diabetes Pipeline
... clinically relevant and statistically significant reductions in HbA1c and fasting blood sugar or fasting plasma glucose (FPG) levels (p-values of less than 0.05%):(1) ...... LDL cholesterol and triglycerides Glycemic Parameters: fasting glucose, fasting insulin and insulin resistance Inflammatory Markers of ...
... treatment with APS who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. Hyperprolactinemia: As with other drugs that ...
Type 2 Diabetes: An Epidemic Among America's Youth
... disease. Researchers are tracking the youth's body mass indices (BMIs), fasting glucose levels and fasting insulin levels to show the health benefits of lifestyle adjustments. ...... those with risk factors for diabetes should undergo baseline and periodic fasting blood glucose testing. Patients who develop symptoms of hyperglycemia during treatment should undergo fasting blood glucose testing. Undesirable alterations in lipids have been ...
Modified Insulin Most Effective For Controlling Post-Meal Blood Sugar Levels
... appear to be more effective than pre-mixed insulin analogues in lowering fasting blood sugar levels. -- Pre-mixed insulin analogues are better than ... are more effective than non-insulin antidiabetic medications in lowering fasting blood sugar levels. -- Pre-mixed insulin analogues are more likely than ...... that the oral formulation of GLP-1 stimulated an early increase in fasting insulin and a decrease in fasting glucose as compared to placebo. "An intravenous or subcutaneous ...
... sustained a similar improvement in glucose control [A1C: -2.0%+/-0.08; fasting plasma glucose (FPG) -47+/-3 mg/dL] compared to those receiving treatment ... on exenatide once weekly showed sustained improvements in A1C and fasting plasma glucose levels at week 52 [A1C: -2.0%+/-0.1; FPG -47+/-3 mg/dL (LS ...
... with exenatide also resulted in a statistically significant lowering of fasting glucose concentrations for EXE 5 mcg (-17.5+/-4 mg/dL) and EXE 10 mcg ... (+4.5+/-14 mg/dL) in patients treated with placebo. In addition, fasting serum lipid profiles, including total cholesterol and high- and ...
... to 2 years. Lantus(R) was injected once-daily and titrated to capillary fasting blood glucose 70-100 mg/dL. In the lifestyle management arm, dietary and ... A1C <7% at endpoint. Secondary endpoints included changes in A1C and fasting plasma glucose (FPG), and hypoglycemia incidence. 211 (52.6% male) ...
... antipsychotics who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and periodically during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. A potentially fatal symptom complex, sometimes ...
... antipsychotics who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and periodically during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. A potentially fatal symptom complex, sometimes ...
Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
... starting on atypical antipsychotics should undergo baseline and periodic fasting blood glucose testing. Patients who develop symptoms of hyperglycemia during treatment should undergo fasting blood glucose testing. Undesirable alterations in lipids have been ...... with risk factors for diabetes should undergo baseline and periodic fasting blood glucose testing. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. There have been few reports of hyperglycemia ...
... starting on atypical antipsychotics should undergo baseline and periodic fasting blood glucose testing. Patients who develop symptoms of hyperglycemia during treatment should undergo fasting blood glucose testing. Undesirable alterations in lipids have been ...
... lowers plasma insulin levels in diet-induced obese (DIO) mice and improves fasting blood glucose and glucose tolerance in hyperglycemic animal models, and ... sensitivity, lowering of plasma insulin levels and durable improvements in fasting blood glucose and glucose tolerance. "This encouraging preclinical work ...
Mayo Clinic Study Finds Further Association Between Diabetes and Pancreatic Cancer
... of 736 patients with pancreatic cancer and 1,875 healthy individuals with fasting blood glucose data in their medical record. Dr. Chari's team found that 40 ... with diabetes, while only 20 percent of the healthy individuals had fasting blood glucose levels in the diabetic range. Type 2 diabetes is far ...... antipsychotics who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and periodically during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. A potentially fatal symptom complex, sometimes ...
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
... antipsychotics who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and periodically during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. A potentially fatal symptom complex, sometimes ...Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
... and pharmacokinetics of R7128 following single ascending doses under fasting conditions. The secondary objective of this study was to explore the ... and pharmacokinetics of R7128 following single ascending doses under fasting conditions. The secondary objective of Part 1 is to explore the ...... (adenosine monophosphate activated protein kinase) for the treatment of diabetes and metabolic diseases. Activation of AMPK has been shown to lower fasting blood glucose levels and improve glucose disposal following a glucose challenge, two key goals in the management of type 2 diabetes. Under the ...
... compounds or its active metabolite have demonstrated reductions in blood pressure, triglycerides, cholesterol levels, C-reactive protein, and fasting blood glucose levels. Enzyme levels indicative of liver damage, such as ALT and AST, are decreased, pointing to an outstanding safety profile. ...
Reliv International's GlucAffect(TM) Proven Effective in Clinical Study
... had pre-diabetic glucose levels prior to the study. Subjects taking GlucAffect, a powdered product mixed with water or other liquids, lowered their fasting blood glucose by an average of 30 percent and they lost an average of 16 pounds. Subjects in the control group reported a marginal decline in blood ...The Lancet Publishes Direct Comparison Study Between Liraglutide and Exenatide
... greater drop in A1C of 1.12% compared to 0.79% in the exenatide group, and liraglutide was also significantly better than exenatide at lowering fasting plasma glucose (-1.61 mmol/L vs -0.60 mmol/L) in this typical type 2 diabetes population. The study comprised 464 patients who were not reaching ...... of treatment with exenatide once weekly for all patients during an open-ended assessment period. Significant reductions in A1C of 1.7 percent and fasting plasma glucose (FPG) of 40 mg/dL were maintained after two years of treatment. Sixty-five percent of patients achieved an A1C of 7 percent or less. ...
... effectively lower blood sugar after two years of treatment is consistent with its other long-term clinical benefits such as continued reductions in fasting blood sugar and weight," said Dr. Alan Garber, Baylor College of Medicine , Houston, a LEAD(TM) 3 principal study investigator. "Even with ...
... in A1C. Secondary objectives were proportion of subjects reaching specific A1C levels and treatment differences in postprandial plasma glucose (PPG), fasting plasma glucose (FPG), and weight. A1C was reduced by -0.66% and -0.72% in the TI+G and BPA 70/30 groups, respectively, and the proportion of ...
New Study Showed Lantus(R) Plus One, Two or Three Shots of Apidra(R) Lowered Patients' Blood Sugar
... 0 were randomized to a 24-week intensified regimen of Lantus(R) plus Apidra(R) administered as above. Dose was adjusted to achieve an A1C<7%, fasting plasma glucose (FPG) and preprandial blood glucose < 110 mg/dl, and bedtime blood glucose < 130 mg/dl. FPG, Lantus(R) dose, and weight did not ...First Human Study to Show 'Sun Chlorella A' Supports Heart Health
... of as little as 8 grams (1/3 ounce) of "Sun Chlorella A" daily resulted in noticeable reductions in body fat percentage, serum total cholesterol, and fasting blood glucose levels. For a 12-week period, 34 participants ingested four grams of "Sun Chlorella A" tablets each morning and evening. ...... in men and <50 mg/dL in women -- Blood pressure greater than or equal to 130/85 mmHg (or on antihypertensive treatment) -- Elevated fasting plasma glucose (greater than or equal to 100 mg/dL). What is meant by number needed to treat? The NNT value provides a clinical ...
Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
... demonstrated meaningful improvement in four primary outcomes used to evaluate type 2 diabetes, including: A 9.5% decrease in fasting blood glucose with a resulting 17% differential compared to placebo subjects in the same cohort; A 7% decrease in the area under the curve ...Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia
... and Metabolic Profile in Diet-Induced Obese Rats" concluded that a single subcutaneous dose of MSI-1436 leads to marked reductions in body weight, fasting blood glucose, serum triglycerides and cholesterol in diet-induced obese (DIO) rats. In the study, the researchers reported that MSI-1436 induced ...New Analysis Estimates Numbers of Older U.S. Adults Who May Benefit From Statin Therapy
... study examined data from a subset of 2,322 older men and women who answered the NHANES survey questionnaires and also allowed researchers to take a fasting blood sample to test for a variety of cardiovascular risk factors, including cholesterol level and level of hsCRP. Using those data, Spatz and ...... significantly better mean daytime blood glucose (BG)(p=0.0033), postprandial blood glucose (PPBG)(p<0.0001) and a more pronounced decrease of fasting blood glucose (FBG) (p=0.0684) versus pre-mixed insulins. Patients on intensified LANTUS(R) and APIDRA(R) therapy also tended to experience fewer ...
... 0.17 Mean change in systolic blood pressure from baseline, mmHg -6.7* -5.6* -1.1 *p FPG, fasting plasma glucose; OAD, oral antidiabetic drug; PPG, post-prandial glucose Safety and tolerability of liraglutide There were no major hypoglycemic ...
Other Contentsflowerflowerflowercytometrycytometrycytometrymodelmodelmodelmodelmodelmodelmodelmodelmodelmodelfluidfluidfluidfluidfluidfluidfluidfluidfluidfoliosefolliclesfolliclesfolliclesfolliclespyramidpyramid
Breaking Biology News(10 mins):Newly discovered mechanism allows cells to change state 2BioGlue 28R 29 Surgical Adhesive Hits 500 000 Procedure Milestone Worldwide Company Data Indicates 50267 1BioGlue 28R 29 Surgical Adhesive Hits 500 000 Procedure Milestone Worldwide Company Data Indicates 50267 2BioGlue 28R 29 Surgical Adhesive Hits 500 000 Procedure Milestone Worldwide Company Data Indicates 50267 3BioGlue 28R 29 Surgical Adhesive Hits 500 000 Procedure Milestone Worldwide Company Data Indicates 50267 4New Drug Promising Against Rheumatoid Arthritis 50263 1New Drug Promising Against Rheumatoid Arthritis 50263 2Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non Small Cell Lung Cancer Drug Market to Nearly Triple to Almost 2 50258 1Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non Small Cell Lung Cancer Drug Market to Nearly Triple to Almost 2 50258 2Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non Small Cell Lung Cancer Drug Market to Nearly Triple to Almost 2 50258 3
Breaking Medicine News(10 mins):Health News:Children's National Named to the 2009 Leapfrog Group Best Hospitals List 2Health News:Children's National Named to the 2009 Leapfrog Group Best Hospitals List 3Health News:McGraw-Hill Education's Online Resources Ease Learning at Home During H1N1 Outbreak 2Health News:Weber Shandwick Is First U.S. Healthcare Practice To Be Trained And Certified In Regulatory Compliance 2Health News:Aurora Health Care and ECRS Complete 112 Location Retail Automation Project 2Health News:Senate Restrictions on Flexible Spending Accounts Spur New Campaign 2Health News:Senate Restrictions on Flexible Spending Accounts Spur New Campaign 3
Other TagsithithithithithithithLaparoscopeJarJarOpusOther Tagspredisposes 2association 2association 3association 4association 5association 6association 7spending 2[0] Children's National Named to the 2009 Leapfrog Group Best Hospitals List[0] McGraw-Hill Education's Online Resources Ease Learning at Home During H1N1 Outbreak[0] Weber Shandwick Is First U.S. Healthcare Practice To Be Trained And Certified In Regulatory Compliance[0] Aurora Health Care and ECRS Complete 112 Location Retail Automation Project[0] Senate Restrictions on Flexible Spending Accounts Spur New Campaign
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |